EPO and chronic kidney disease: We found that a CKD mouse model treated with EPO or a HIF‐PHDi to restore proper iron utilization had a 70% reduction of circulating iFGF23, normalization of vitamin D metabolic enzymes, and no exacerbation of hyperphosphatemia.